Durvalumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6168]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable TS ID 11989Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with chemoradiation for untreated muscle-invasive non-metastatic bladder cancer TS ID 11953Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID4065]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with enfortumab vedotin for untreated metastatic urothelial cancer ID6332Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sacituzumab govitecan for treating unresectable metastatic urothelial cancer [ID6150]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC